SCHEMBL2019393

SCHEMBL2019393

CCc1ccc(-c2nnc(-c3cn4c5c(cccc35)CCC4)o2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
MTNR1A P48039 5/20 0.39
MTNR1B P49286 5/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
ADCY8 P40145 1/20 0.37
ADCY1 Q08828 1/20 0.37
MEN1 O00255 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
CASP1 P29466 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2020405 0.88 NPC1 (0.43) HTR2AHTR2CMTNR1AMTNR1BKDM4E
SCHEMBL2021453 0.86 RAB9A (0.49) HTR2AHTR2CMTNR1AMTNR1BKDM4E
SCHEMBL2019352 0.85 NPC1 (0.46) HTR2AHTR2CMTNR1AMTNR1BKDM4E
SCHEMBL2020602 0.85 NPC1 (0.44) HTR2AHTR2CMTNR1AMTNR1BKDM4E
SCHEMBL2015858 0.85 RAB9A (0.48) HTR2AHTR2CKDM4EALDH1A1HPGD
SCHEMBL2016725 0.85 S1PR1 (0.46) HTR2AHTR2CMTNR1AMTNR1BKDM4E
SCHEMBL2018141 0.85 NPC1 (0.46) HTR2AHTR2CMTNR1AMTNR1BKDM4E
SCHEMBL2019229 0.83 KDM4E (0.47) HTR2AHTR2CKDM4EALDH1A1HPGD
SCHEMBL2015370 0.81 NPC1 (0.48) HTR2AHTR2CKDM4EALDH1A1HPGD
SCHEMBL2021179 0.81 RAB9A (0.51) HTR2AHTR2CMTNR1AMTNR1BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 HTR2A 1440/4885HTR2C 632/4885MTNR1A 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.